Abstract: Background and Aims: Huauzontle (Chenopodium berlandieri subsp. nuttalliae) is a pseudocereal native to Mexico and is part of its culinary tradition. This pseudocereal is recognized for its high nutritional value and components that are associated with beneficial health effects. However, there is currently no literature on the impact that the fermentation process would have on its bioactive properties. Therefore, the aim of this research was to evaluate the effect of fermentation by Lactiplantibacillus plantarum Lp22 in huauzontle seeds suspended in water on their antioxidant and anti-inflammatory properties in vitro. Methods: Huauzontle seeds were suspended in water (0.3%, w/v), inoculated with L. plantarum Lp22 (1%, v/v) at 108 CFU/ml, and allowed to ferment for 24 h at 37 °C. Then, seeds were recovered by filtration, grounded and aqueous extract was obtained. The antioxidant activity of the extracts was determined by the ABTS and ORAC methods. Moreover, the inhibition of the enzymes lipoxygenase (LOX) and trypsin was evaluated and the total phenolic compounds in methanolic extract (Folin-Ciocalteu method) were also determined. Key results: The antioxidant activity represented as (M of Trolox equivalents was 812.50 and 927.50 by ABTS and 1384.32 and 3391.11 for ORAC, for unfermented and fermented huauzontle, respectively (p<0.05). The inhibition of LOX activity was 40.06% and 37.24% for unfermented and fermented huauzontle, respectively, while for trypsin it was 12.53% and 14.38% (p>0.05). Besides, total phenol content was 7.49 and 20.24 (g/ml (p<0.05), respectively. Conclusions: Our findings evidence that fermentation of huauzontle improves the antioxidant and anti-inflammatory properties, which may be associated with increased phenol content. Therefore, its consumption could enhance the antioxidant and immune system of the human organism.

Resumen: Antecedentes y Objetivos: El huauzontle (Chenopodium berlandieri subsp. nuttalliae) es un pseudocereal nativo de México y forma parte de su tradición culinaria. Este pseudocereal es reconocido por su alto valor nutricional y componentes que se asocian a efectos benéficos a la salud. Sin embargo, al momento no se cuenta con literatura sobre el impacto que tendría el proceso de fermentación sobre sus propiedades bioactivas. Por ello, el objetivo de la presente investigación fue evaluar el efecto de la fermentación por Lactiplantibacillus plantarum Lp22, en semillas de huauzontle suspendidas en agua, sobre sus propiedades antioxidantes y antiinflamatorias in vitro. Métodos: Semillas de huauzontle se suspendieron en agua (0.3% p/v), se inocularon con L. plantarum Lp22 (1% v/v) a una concentración de 108 UFC/ml y se fermentaron por 24 h a 37 °C. Finalmente, las semillas fueron recuperadas por filtración, se molieron y del extracto acuoso se determinó la actividad antioxidante por los métodos de ABTS y ORAC. Además, se evaluó la inhibición de las enzimas lipooxigenasa (LOX) y tripsina y se determinó la concentración de fenoles totales (método de Folin-Ciocalteu) en extractos metanólicos. Resultados clave: La actividad antioxidante representada como (M de equivalentes Trolox fue de 812.50 y 927.50 por ABTS, y 1384.32 y 3391.11, para ORAC, para huauzontle no fermentado y fermentado, respectivamente (p<0.05). La inhibición de la actividad de LOX fue de 40.06% y 37.24%, y para tripsina fue de 12.53% y 14.38% (p>0.05), para no fermentado y fermentado, respectivamente, mientras que el contenido de fenoles totales fue de 7.49 y 20.24 (g/ml (p<0.05), respectivamente. Conclusiones: Estos hallazgos indican que la fermentación del huauzontle mejora las propiedades antioxidantes y antiinflamatorias, y que pueden estar asociados con el incremento en el contenido de fenoles, por lo que su consumo podría fortalecer el mecanismo antioxidante y sistema inmune del organismo humano.

Abstract: Objective: To review evidence on the efficacy of HPV vaccines in the prevention of non-cancer lesions (anogenital warts [AGW], recurrent laryngeal papillomatosis and oral papillomatosis). Materials and methods: We conducted a systematic review of randomized trials. We performed random effect models and effects were reported as relative risks (RR) and their confidence intervals (95%CI) following both intention to treat (ITT) and per protocol (PP) analyses. Results: We included six studies (n=27 078). One study was rated as high risk of bias. One study could not be included in the meta-analysis because it provided combined results. We found that quadrivalent vaccine reduced the risk of AGW by 62% (RR: 0.38, 95%CI:0.32-0.45, I2:0%) in the ITT analysis and by 95% (RR: 0.05, 95%CI:0.01-0.25, I2:66%) in the PP analysis. Subgroup analyses of studies in women or with low-risk of bias provided similar results. Conclusion: HPV quadrivalent vaccine is efficacious in preventing AGW in men and women.

Resumen: Objetivo: Revisar la evidencia sobre la eficacia de las vacunas contra el virus del papiloma humano en la prevención de lesiones no oncológicas (verrugas anogenitales [VAG], papilomatosis recurrente respiratoria y papilomatosis oral). Material y métodos: Realizamos una revisión sistemática de ensayos clínicos aleatorizados. Empleamos modelos de efectos aleatorios, calculando riesgos relativos (RR) y sus intervalos de confianza al 95% (IC95%), utilizando el análisis por intención a tratar (ITT) y por protocolo (PP). Resultados: Seleccionamos seis estudios (n=27 078). Un estudio tuvo alto riesgo de sesgo y otro no fue incluido en el metanálisis. La vacuna cuadrivalente reduce el riesgo de VAG en 62% (RR: 0,38; IC95%:0,32-0,45; I2:0%) en el análisis ITT y en 95% (RR: 0,05; IC95%:0,01-0,25; I2:66%) en el análisis PP. Los análisis de subgrupos (mujeres y estudios con bajo riesgo de sesgo) proporcionaron resultados similares. Conclusión. La vacuna cuadrivalente es eficaz en la prevención de VAG en hombres y mujeres.

Abstract: Objective: To review evidence on the efficacy of HPV vaccines in the prevention of non-cancer lesions (anogenital warts [AGW], recurrent laryngeal papillomatosis and oral papillomatosis). Materials and methods: We conducted a systematic review of randomized trials. We performed random effect models and effects were reported as relative risks (RR) and their confidence intervals (95%CI) following both intention to treat (ITT) and per protocol (PP) analyses. Results: We included six studies (n=27 078). One study was rated as high risk of bias. One study could not be included in the meta-analysis because it provided combined results. We found that quadrivalent vaccine reduced the risk of AGW by 62% (RR: 0.38, 95%CI:0.32-0.45, I2:0%) in the ITT analysis and by 95% (RR: 0.05, 95%CI:0.01-0.25, I2:66%) in the PP analysis. Subgroup analyses of studies in women or with low-risk of bias provided similar results. Conclusion: HPV quadrivalent vaccine is efficacious in preventing AGW in men and women.

Resumen: Objetivo: Revisar la evidencia sobre la eficacia de las vacunas contra el virus del papiloma humano en la prevención de lesiones no oncológicas (verrugas anogenitales [VAG], papilomatosis recurrente respiratoria y papilomatosis oral). Material y métodos: Realizamos una revisión sistemática de ensayos clínicos aleatorizados. Empleamos modelos de efectos aleatorios, calculando riesgos relativos (RR) y sus intervalos de confianza al 95% (IC95%), utilizando el análisis por intención a tratar (ITT) y por protocolo (PP). Resultados: Seleccionamos seis estudios (n=27 078). Un estudio tuvo alto riesgo de sesgo y otro no fue incluido en el metanálisis. La vacuna cuadrivalente reduce el riesgo de VAG en 62% (RR: 0,38; IC95%:0,32-0,45; I2:0%) en el análisis ITT y en 95% (RR: 0,05; IC95%:0,01-0,25; I2:66%) en el análisis PP. Los análisis de subgrupos (mujeres y estudios con bajo riesgo de sesgo) proporcionaron resultados similares. Conclusión. La vacuna cuadrivalente es eficaz en la prevención de VAG en hombres y mujeres.

Information about resistance profile of darunavir (DRV) is scarce in Brazil. Our objectives were to estimate the prevalence of DRV resistance mutations in patients failing protease inhibitors (PI) and to identify factors associated with having more DRV resistance mutations. All HIV-infected patients failing PI-based regimens with genotyping performed between 2007 and 2008 in a referral teaching center in São Paulo, Brazil, were included. DRV-specific resistance mutations listed by December 2008 IAS-USA panel update were considered. Two Poisson regression models were constructed to assess factors related to the presence of more DRV resistance mutations. A total of 171 HIV-infected patients with available genotyping were included. The number of patients with lopinavir, saquinavir, and amprenavir used in previous regimen were 130 (76%), 83 (49%), and 35 (20%), respectively. The prevalence of major DRV resistance mutations was 50V: 5%; 54M: 1%; 76V: 4%; 84V: 15%. For minor mutations, the rates were 11I: 3%; 32I: 7%; 33F: 23%; 47V: 6%; 54L: 6%; 74P: 3%; 89V: 6%. Only 11 (6%) of the genotypes had > 3 DRV resistance mutations. In the clinical model, time of HIV infection of > 10 years and use of amprenavir were independently associated with having more DRV resistance mutations. In the genotyping-based model, only total number of PI resistance mutations was associated with our outcome. In conclusion, the prevalence of DRV mutations was low. Time of HIV infection, use of amprenavir and total number of PI resistance mutations were associated with having more DRV mutations.